Skip to main content

RA Capital Healthcare Fund LP's Form 4 filing

Climb Bio, Inc. (CLYM) · filed Aug 16, 2021

Accession no.
0001104659-21-106405
Filed
Aug 16, 2021, 4:47 PM ET
Trade date
Aug 12, 2021
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 8 derivative transactions. Open-market purchases total $40.0M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
RA Capital Healthcare Fund LPCIK 0001315082Director, 10% Owner
Ra Capital Management, L.P.CIK 0001346824Director, 10% Owner
Kolchinsky PeterCIK 0001384859Director, 10% Owner
Shah Rajeev M.CIK 0001619841Director, 10% Owner
RA Capital Nexus Fund, L.P.CIK 0001780117Director, 10% Owner
RA Capital Nexus Fund II, L.P.CIK 0001825376Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 12, 2021Common StockCConversionAcquired+4,727,585–F1–7,594,804Indirect
Aug 12, 2021Common StockPPurchaseAcquired+3,004,782$12.50+$37,559,77510,599,586Indirect
Aug 12, 2021Common StockCConversionAcquired+1,226,497–F1–1,226,497Indirect
Aug 12, 2021Common StockCConversionAcquired+288,461–F1–288,461Indirect
Aug 12, 2021Common StockPPurchaseAcquired+195,218$12.50+$2,440,225483,679Indirect
Aug 12, 2021Common StockCConversionAcquired+624,974–F1–841,087Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 12, 2021Common StockCConversionDisposed−2,639,507$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−1,415,002$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−673,076$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−708,333$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−518,164$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−288,461$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−485,493$0.00$00Indirect
Aug 12, 2021Common StockCConversionDisposed−139,481$0.00$00Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On August 12, 2021, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

Referenced by the price of 4 transactions in Table I.

Remarks

Andrew Levin, a Managing Director of the Adviser, serves on the Issuer's board of directors.

Read the full filing on SEC EDGAR (opens in a new tab)